دورية أكاديمية
National retrospective registry survey on the epidemiology of sarcoidosis in Finland 2002-2022.
| العنوان: | National retrospective registry survey on the epidemiology of sarcoidosis in Finland 2002-2022. |
|---|---|
| المؤلفون: | Salonen J; Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu, Finland johanna.salonen@oulu.fi.; Center of Internal and Respiratory Medicine and Medical Research Center (MRC) Oulu, Oulu University Hospital, Oulu, Finland., Kaarteenaho R; Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu, Finland.; Center of Internal and Respiratory Medicine and Medical Research Center (MRC) Oulu, Oulu University Hospital, Oulu, Finland. |
| المصدر: | BMJ open respiratory research [BMJ Open Respir Res] 2024 Aug 21; Vol. 11 (1). Date of Electronic Publication: 2024 Aug 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BMJ Publishing Group Ltd & British Thoracic Society Country of Publication: England NLM ID: 101638061 Publication Model: Electronic Cited Medium: Internet ISSN: 2052-4439 (Electronic) Linking ISSN: 20524439 NLM ISO Abbreviation: BMJ Open Respir Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BMJ Publishing Group Ltd & British Thoracic Society, [2013]- |
| مواضيع طبية MeSH: | Sarcoidosis*/epidemiology , Registries*, Humans ; Finland/epidemiology ; Male ; Female ; Retrospective Studies ; Middle Aged ; Adult ; Young Adult ; Adolescent ; Incidence ; Aged ; Prevalence ; Age Distribution ; Sex Distribution ; Sarcoidosis, Pulmonary/epidemiology |
| مستخلص: | Background: The prevalence of sarcoidosis is known to be high in the Nordic countries. There are no recent research data on the incidence or prevalence of sarcoidosis in Finland. Our aim was to investigate the epidemiology of sarcoidosis in Finland through a retrospective registry-based study. Methods: We made an information request to the Hilmo database on patients who had been treated in Finnish specialised care with a main diagnosis related to sarcoidosis. Data were requested for the period 1 January-31 December for the years 2002, 2012 and 2022. In addition, we examined the age and gender distribution and regional differences in these variables between the five university hospital districts covering the whole of Finland. Results: The incidence of sarcoidosis was 17‒19/100 000/year throughout the follow-up period. The prevalence of sarcoidosis in the ≥18-year-old population had risen from 85/100 000 in 2002-106/100 000 in 2022. There were considerable differences between university hospital districts: The highest prevalence rate was 170/100 000 in the Tampere University Hospital district in 2022, which was twice as high as in the Helsinki University Hospital district (84/100 000). The proportion of pulmonary sarcoidosis in all sarcoidosis cases decreased from 62% to 45% while the proportion of multiorgan sarcoidosis (D86.8) increased from 11% to 34%. The incidence of sarcoidosis was 15/100 000 and the prevalence was 82/100 000 in the age groups of ≥60 years in 2002. In 2022, the incidence in this same age group had risen to 20/100 000 and the prevalence to 109/100 000. In the ≥60-year-old population, the proportion of D86.8 increased from 11% to 35%. Conclusions: Sarcoidosis was a more common disease in Finland than in previous studies. Multiorgan sarcoidosis among the elderly has increased over the past 20 years. This might be explained by changes in environmental factors associated with sarcoidosis. Significant regional differences in prevalence might be partly explained by familial clustering. Competing Interests: Competing interests: JS reports congress fees and travel costs from Sanofi and GlaxoSmithKline, outside of the submitted work. RK has received lecture fees from Boehringer-Ingelheim and Roche, advisory board fees from MSD and Boehringer-Ingelheim and virtual congress costs from Novartis outside of the submitted work. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| References: | Eur Respir J. 2008 Feb;31(2):372-9. (PMID: 17959635) Am J Respir Crit Care Med. 1999 Aug;160(2):736-55. (PMID: 10430755) Pol Arch Intern Med. 2019 Sep 30;129(9):580-585. (PMID: 31436761) Respir Med. 1999 Jun;93(6):408-12. (PMID: 10464823) Health Syst Transit. 2019 Aug;21(2):1-166. (PMID: 31596240) Sarcoidosis Vasc Diffuse Lung Dis. 2003 Mar;20(1):46-52. (PMID: 12737280) ERJ Open Res. 2022 Jan 24;8(1):. (PMID: 35083316) Scand J Public Health. 2012 Aug;40(6):505-15. (PMID: 22899561) Ann Am Thorac Soc. 2016 Aug;13(8):1244-52. (PMID: 27509154) Respir Med. 2021 Oct;187:106548. (PMID: 34352562) Eur Clin Respir J. 2023 Mar 17;10(1):2190210. (PMID: 36950471) Eur Respir J. 2021 Dec 16;58(6):. (PMID: 34140301) Mayo Clin Proc. 2016 Feb;91(2):183-8. (PMID: 26727158) Eur Respir J. 2019 Oct 24;54(4):. (PMID: 31391219) Respir Res. 2018 Aug 28;19(1):158. (PMID: 30153830) Eur Respir J. 2016 Dec;48(6):1690-1699. (PMID: 27471207) J Clin Med. 2020 Feb 01;9(2):. (PMID: 32024123) Sarcoidosis. 1995 Mar;12(1):61-7. (PMID: 7617979) Curr Opin Pulm Med. 2023 Sep 1;29(5):493-500. (PMID: 37410457) |
| فهرسة مساهمة: | Keywords: Clinical Epidemiology; Rare lung diseases; Sarcoidosis |
| تواريخ الأحداث: | Date Created: 20240822 Date Completed: 20240822 Latest Revision: 20240824 |
| رمز التحديث: | 20240826 |
| مُعرف محوري في PubMed: | PMC11340709 |
| DOI: | 10.1136/bmjresp-2024-002461 |
| PMID: | 39174054 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2052-4439 |
|---|---|
| DOI: | 10.1136/bmjresp-2024-002461 |